Adverse effects of local or systemic application of rapamycin for the prevention of neointimal hyperplasia.
Walpoth
Beat H
BH
D000818:Animals; D023903:Coronary Restenosis / Q000517:prevention & control; D004305:Dose-Response Relationship, Drug; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D008660:Metabolism / Q000187:drug effects; D051379:Mice; D020123:Sirolimus / Q000008:administration & dosage / Q000009:adverse effects*; D015607:Stents; D013927:Thrombosis / Q000139:chemically induced*; D017539:Tunica Intima / Q000473:pathology*
D007166:Immunosuppressive Agents; D020123:Sirolimus